TEM

$46.96-1.78 (-3.65%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Tempus AI, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$46.96
Potential Upside
5%
Whystock Fair Value$49.31
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare p...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-40.65%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.00

Recent News

Insider Monkey
Mar 20, 2026

H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95

Tempus AI, Inc. (NASDAQ:TEM) is among the 10 Best New AI Stocks to Buy. On March 9, H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI, Inc. (NASDAQ:TEM) to $95 from $89 while maintaining a Buy rating. The analyst highlighted the company’s expanding network of strategic partnerships, including collaborations with Merck & Co., […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 18, 2026

Tempus AI Pediatric Leukemia Registry Deepens Oncology Data And Patient Reach

Tempus AI and Blood Cancer United have launched an AI powered real world registry for pediatric acute myeloid leukemia. The registry is designed to centralize clinical and patient reported data to support research and empower affected families. Tempus AI is deploying its olivia platform to help patients and caregivers engage with their health information and care teams. Tempus AI, listed as NasdaqGS:TEM, is building this registry at a time when the stock trades around $48.69 per share. The...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 18, 2026

Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

Wondering if Tempus AI is attractively priced or just riding hype? This article walks you through what the numbers actually say about its current valuation. The stock closed at US$50.84, with a 0.1% decline over 7 days, a 2.1% decline over 30 days, and an 18.5% decline year to date, though it is up 11.2% over the past year. Recent coverage of Tempus AI has focused on its role in applying artificial intelligence to healthcare data. This has kept investor attention on how the business model...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 17, 2026

Is Tempus AI (TEM) The Best AI Healthcare Stock in Cathie Wood’s Portfolio?

Tempus AI (NASDAQ:TEM) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Tempus AI (NASDAQ:TEM) uses AI to analyze and process large datasets to find patterns that help doctors treat patients more efficiently. ARK increased its stake in Tempus AI (NASDAQ:TEM) by 6% in the fourth quarter to about $446.28 million. […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

BEARISH
Negative press. News cycle fixated on risk factors or misses.